CD22: A Regulator of Innate and Adaptive B Cell Responses and Autoimmunity
CD22 (Siglec 2) is a receptor predominantly restricted to B cells. It was initially characterized over 30 years ago and named “CD22” in 1984 at the 2nd International workshop in Boston (1). Several excellent reviews have detailed CD22 functions, CD22-regulated signaling pathways and B cell subsets r...
Main Authors: | Edward A. Clark, Natalia V. Giltiay |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.02235/full |
Similar Items
-
Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling
by: Natalia V. Giltiay, et al.
Published: (2017-05-01) -
CD47 Deficiency Ameliorates Ocular Autoimmune Inflammation
by: Yoko Okunuki, et al.
Published: (2021-05-01) -
CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
by: Yao Sun, et al.
Published: (2021-10-01) -
CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults
by: Francesco Lanza, et al.
Published: (2020-01-01) -
The Role of CD2 Family Members in NK-Cell Regulation of B-Cell Antibody Production
by: Dorothy Yuan
Published: (2013-12-01)